Bavarian Nordic A/S (OTCMKTS:BVNRY) Short Interest Update

Bavarian Nordic A/S (OTCMKTS:BVNRY) was the target of a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 6,200 shares, an increase of 1,450.0% from the November 15th total of 400 shares. Based on an average daily volume of 51,200 shares, the days-to-cover ratio is presently 0.1 days.

Bavarian Nordic A/S Stock Down 1.7 %

Shares of BVNRY traded down $0.16 during midday trading on Wednesday, reaching $9.05. 11,914 shares of the stock were exchanged, compared to its average volume of 32,858. The company has a market cap of $2.14 billion, a price-to-earnings ratio of 13.11 and a beta of 1.65. The firm has a 50 day simple moving average of $9.84 and a 200-day simple moving average of $9.97. Bavarian Nordic A/S has a 12-month low of $6.86 and a 12-month high of $14.60.

Bavarian Nordic A/S Company Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.